The 2018 Nobel Prize in Medicine was awarded to Drs. Allison and Honjo for their pioneering discoveries that led to the development of cancer immunotherapy. From the early years of cytokine and monoclonal antibody therapies, to the recent immune checkpoint inhibitors, adoptive cell transfer, and cancer vaccine therapies, cancer immunotherapies have brought paradigm shifts to cancer treatment. Cancer immunology and immuno-oncology research also lead the efforts in early technology development and adoption. Cutting edge high throughput sequencing, genome engineering, single cell genomics, imaging, and proteomics techniques are being applied to cancer immunology and immuno-oncology research and clinical applications. As a result, computational analyses and quantitative modeling have become the critical bottlenecks in understanding tumor immune microenvironment and immunotherapy response. Many important yet challenging questions remain to be answered. What is the immune cell composition in the tumor microenvironment? How do cancer cells and different immune cells interact with each other, and which mutations are immunogenic? How do T cell receptors and B cell receptors recognize tumor antigens? How to predict patient response to immunotherapies? Are there new drug targets to improve immunotherapy response? The 2019 Conference of the Program in Quantitative Genomics will focus on the computational algorithms, quantitative models, as well as data integration techniques that are under active development to answer these important questions. The conference will be centered on the following three topics: SESSION I: Tumor immune deconvolution and single cell analyses SESSION II: Regulators and biomarkers of immunotherapy response SESSION III: Neoantigen prediction and immune repertoire modeling Keynote Speakers: Nir Hacohen Massachusetts General Hospital, Harvard Medical School, Broad Institute Antoni Ribas University of California, Los Angeles Fabian Theis Helmholtz Zentrum München Distinguished Speakers: Michael Angelo Stanford University Maksym Artyomov Washington University School of Medicine Phil Bradley Fred Hutchinson Cancer Research Center Benjamin Greenbaum Mount Sinai School of Medicine Christina Leslie Memorial Sloan Kettering Cancer Center Aaron Newman Stanford University Morten Nielsen Technical University of Denmark Paul Thomas St. Jude Children’s Research Hospital Benjamin Vincent UNC Chapel Hill Panelists: Ana Anderson Harvard Medical School, Brigham and Women’s Hospital Laurie Glimcher Dana-Farber Cancer Institute, Harvard Medical School Xiaole Shirley Liu Dana-Farber Cancer Institute and Harvard School of Public Health Ilya Shmulevich Institute for Systems Biology